Nebenwirkungen · Aldara
ALDARA 5% cream · Abschnitt 4.8 · PDF-Seite 7–8
HOS-088041 · Präparat HOS-083607
In trials with 5 times per week dosing 58% of patients experienced at least one adverse event. The most frequently reported adverse events from the trials judged probably or possibly related to imiquimod cream are application site disorders, with a frequency of 28.1%. Some systemic adverse reactions, including back pain (1.1%) and influenza-like symptoms (0.5%) were reported by imiquimod cream patients. Patient reported adverse reactions from 185 patients treated with imiquimod cream in placebo controlled phase III clinical studies for superficial basal cell carcinoma are presented below. These adverse events are considered at least possibly causally related to treatment with imiquimod. Actinic keratosis 7 In the pivotal trials with 3 times per week dosing for up to 2 courses each of 4 weeks, 56% of imiquimod patients reported at least one adverse event. The most frequently reported adverse event from these trials judged probably or possibly related to imiquimod cream was application site reactions (22% of imiquimod treated patients). Some systemic adverse reactions, including myalgia (2%) were reported by imiquimod treated patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-18T11:40:00Z · SHA-256 29a2c6949b9e74d0aba2dc8c33290a7bc20b103110a06b748f4e53afb53b0ce7 · Passage d9cad9a39e14396574334b6c2425fef105700aad1191a3a1317d6903c65ad935 · Zeichen 744–1947 im Abschnitt